[6-K] Bright Minds Biosciences Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Bright Minds Biosciences Inc. filed a Form 6-K attaching its Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2025 and 2024 and its Management's Discussion and Analysis for the second quarter ended March 31, 2025. The filing lists Exhibits 99.1–99.4, including CEO and CFO certifications, and states these interim documents are incorporated by reference into the company’s Form F-3 registration statement (File No. 333-284694). The report is signed by CFO Ryan Cheung and dated August 8, 2025.

Positive

• Filed interim consolidated financial statements for the six months ended March 31, 2025 and 2024 (Exhibit 99.1)
• Filed MD&A for the second quarter ended March 31, 2025 (Exhibit 99.2)
• Incorporated the interim documents by reference into the Form F-3 registration statement (File No. 333-284694), aligning disclosures with the prospectus

Negative

• No financial metrics or summary figures

Insights

Financial Analyst

TL;DR: Routine Form 6-K filing that attaches interim financials and MD&A and incorporates them into the company’s F-3.

The filing itself provides no summarized financial metrics in-line; instead it submits the formal interim consolidated financial statements (six months ended March 31, 2025 and 2024) and the MD&A for Q2 2025 as exhibits. Incorporation by reference into Form F-3 means these documents form part of the company’s registered offering record. Without the attached exhibits, investors cannot assess performance from this 6-K alone.

Corporate Governance Expert

TL;DR: Governance procedures appear followed: interim statements, MD&A and CEO/CFO certifications were filed and signed.

The Form 6-K identifies Exhibits 99.1–99.4, including CEO and CFO certifications, and is signed by the CFO on August 8, 2025, indicating formal attestation steps were completed for these interim filings. The document explicitly notes incorporation by reference into the issuer’s Form F-3 registration statement, aligning disclosure with the registrant’s prospectus record.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2025

Commission File No. 001-40997

BRIGHT MINDS BIOSCIENCES INC.
(Translation of registrant's name into English)

19 Vestry Street,
New York, NY  10013
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  [ X ]  Form 40-F [    ]

Attached as Exhibit 99.1 and 99.2 to this Report of Foreign Private Issuer on Form 6-K is our Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2025 and 2024 (the "Interim Financials"), and our Management's Discussion and Analysis for the Second Quarter Ended March 31, 2025 (the "Interim MD&A"), respectively. The information in the Interim Financials and Interim MD&A on Form 6-K and the exhibits hereto are incorporated by reference into our registration statement on Form F-3 (File No. 333-284694), originally filed on February 5, 2025, and the prospectus thereto filed on February 14, 2025.

SUBMITTED HEREWITH

Exhibits
99.1	Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2025 and 2024
99.2	Management's Discussion and Analysis for the Second Quarter Ended March 31, 2025
99.3	Certification of Interim Filings - CEO
99.4	Certification of Interim Filings - CFO

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BRIGHT MINDS BIOSCIENCES INC.

/s/ Ryan Cheung
__________________________
Ryan Cheung
Chief Financial Officer

Date:  August 8, 2025

FAQ

What did Bright Minds (DRUG) file on this Form 6-K?

The company attached Exhibit 99.1 (Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2025 and 2024), Exhibit 99.2 (MD&A for the second quarter ended March 31, 2025), and certifications 99.3 and 99.4.

Are the interim financials incorporated into any registration statement?

Yes. The filing states these interim documents are incorporated by reference into the company’s Form F-3 registration statement (File No. 333-284694).

Does this 6-K include financial results or earnings figures?

No. The 6-K text does not present financial figures; the actual numbers and analysis are contained in Exhibit 99.1 and Exhibit 99.2.

Who signed the Form 6-K and when?

The report is signed on behalf of the registrant by Ryan Cheung, Chief Financial Officer, and dated August 8, 2025.

Where can I find the MD&A for Q2 2025 referenced in the filing?

The MD&A for the second quarter ended March 31, 2025 is attached as Exhibit 99.2 to this Form 6-K and is incorporated by reference into the Form F-3 registration statement.